D. Carballo

Discipline

Psychologie (3) Economies et finances (2)

Type de document

Articles (16) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Patients (14) Patients (14) risque (11) Risk (11) cohorte (11) Syndromes (10) mortalité (7) âge (7) Mortality (7) Year (7) Mortality (7) Human beings (7) Myocardial infarction (7) Age (7) Age (7) Ci (Chinese poetry) (6) Treatment (5) Rates (5) Cerebrovascular disease (5) Rates (5) Models (5) temps (durée) (4) tabagisme (4) association (4) danger (4) taux (4) Death (4) Methods (4) Time (4) Swiss (4)

Documents écrit par D. Carballo (16) | parle de D. Carballo (0)

Smoking cessation and depression after acute coronary syndrome.
K. Krasieva et al.
Long-term effects of systematic smoking cessation counselling during acute coronary syndrome, a multicentre before-after study.
L. Gilgien-Dénéréaz et al. (18 juil. 2022)
Recommandations européennes 2021 pour la prévention cardiovasculaire : nouveautés [European guidelines 2021 for the cardiovascular prevention: new concepts]
E. Vasilakou et al. (9 mars 2022)
Cardiovascular therapy use, modification, and in-hospital death in patients with COVID-19: A cohort study.
C. Follonier et al. (2022)
Symptoms and quality of life at 1-year follow up of patients discharged after an acute COVID-19 episode.
E. Tessitore et al. (6 déc. 2021)
Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute Coronary Events) 2.0 Risk Score in Patients With Acute Coronary Syndromes.
R. Klingenberg et al. (19 oct. 2021)
CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients.
T. Mahendiran et al.
Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events.
R. Klingenberg et al.
Optimal Timing of Invasive Coronary Angiography following NSTEMI.
T. Mahendiran et al. (2020)
Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes.
N. Vuilleumier et al. (9 juil. 2019)
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention.
D. Carballo et al. (2019)
Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.
S. Canivell et al. (2018)
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
B. Gencer et al. (9 nov. 2017)
Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study.
D. Carballo et al. (2015)
Acute respiratory and cardiovascular admissions after a public smoking ban in geneva, Switzerland.
J.P. Humair et al. (2014)
Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications.
R. Auer et al. (2014)